Table 4.
Studies investigating prognostic value of H-FABP in acute decompensated CHF and chronic stable CHF.
| First Author, Year | Population (n) | Primary outcome | Follow up | Biomarker | Risk estimate, 95% CI |
|---|---|---|---|---|---|
| Setsuta, 2002 [84] | Stable chronic CHF (56) | All-cause death CHF readmission |
16 ± 12-mo | H-FABP | HR 2.6, 1.1–6.5 per 3.86ng/ml increase |
| cTn | HR 7, 1.1–44 | ||||
| BNP | NS | ||||
| ANP | NS | ||||
| CK-MB | NS | ||||
| Arimoto, 2005 [85] | Acute CHF (179) | Cardiac death CHF readmission |
20-mo | H-FABP | HR 7.39, p = 0.0065 |
| LDH | NS | ||||
| CK | NS | ||||
| Niizaki, 2005 [86] | Acute CHF (186) | Cardiac death CHF readmission |
534 ± 350 days | H-FABP | HR 5.42, 2.20–13.32 |
| BNP | HR 2.41, 1.02–5.73 | ||||
| Komamura, 2006 [87] | Chronic stable non-ischaemic DCM (92) | Cardiac death Heart transplant LV assist device |
48 months | H-FABP | RR 7.5, 0.7–36.1 |
| BNP | RR 10.9, 3.5–35.3 | ||||
| cTn | NS | ||||
| Niizeki, 2007 [88] | Acute CHF (126) | Cardiac death CHF readmission |
474 ± 328-days | H-FABP | HR 15.7, 3.8–64.5 |
| BNP | HR 2.6, 0.87–7.8 | ||||
| cTn | NS | ||||
| Niizek, 2008 [89] | Acute CHF (113) (Admission + discharge) |
Cardiac death CHF readmission |
624 ± 299 days | H-FABP (at discharge) | HR 5.7, 2–9.5 |
| BNP (at discharge) | OR 4.62, 1.49–14.33a | ||||
| Setsuta, 2008 [90] | Chronic stable CHF (103) | All-cause death CHF readmission |
28 ± 26 mo | H-FABP | HR 2.24, 1.21–4.14 |
| cTn | HR 1.95, 1.02-3.71 | ||||
| Kutsuzawa, 2012 [91] | Chronic CHF with preserved EF (151) | Cardiac death CHF readmission |
694 (29-2000) days | H-FABP | HR 1.165, 1.034–1.314 |
| cTn | NS | ||||
| BNP | NS | ||||
| hs-CRP | NS | ||||
| Hoffmann, 2015 [82] | Acute CHF (122) | All-cause death CHF readmission |
5-yrs | H-FABP | ACM-NS CHF readmit-HR 1.07, 1.02-1.13 |
| cTn | CHF readmit /ACM-NS | ||||
| NT-proBNP | CHF readmit/ACM-NS | ||||
| Otaki, 2014 [92] | Chronic stable CHF ± AF (402) | All-cause death Cardiac death CHF readmission |
643 days-AF 488 days-SR |
H-FABP-AF HFABP-SR | HR 1.57, 1.2–2 HR 1.28, 1.04–1.58 |
| cTn-AF cTn-SR |
HR 1.4, 1.13, 1.74 NS |
||||
| BNP-AF/SR | NS | ||||
| Shirakabe, 2015 [93] | CHF ± AKI admitted to ICU (NYHA III/IV) | All-cause death CHF readmission |
90-days | H-FABP | HR 5.1, 1.86–14.17 |
| hs-Tn | NS | ||||
| BNP | NS | ||||
| Kadowaki, 2017 [94] | Acute CHF (322) | Cardiac death CHF readmission |
534 (203-1014) days | H-FABP | HR 1.745, 1.088–2.7903 |
| BNP | NS | ||||
| Kazimierczyk, 2018 [95] | Acute NYHA III/IV CHF (71) Admission + discharge |
CV death CHF readmission |
9.2 ± 7.3-mo | H-FABP (at discharge) | (OR 1.3, 1.06–1.68) |
| BNP | NS |
Unless specified, risk estimates in last column are for composite end-point, and are those achieved after multi-variate analyses, including co-markers checked in each study.
aOR for Niizeki, 2008 calculated from reported raw data.